Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer

NCT ID: NCT01512745

Last Updated: 2016-10-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 267 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2013-05-31

Brief Summary

Apatinib is a tyrosin-inhibitor agent targeting at vascular endothelial growth factor receptor (VEGFR), and it's anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the maximum tolerable daily dose is 850 mg. The purpose of this study is to determine whether apatinib can improve progression free survival or overall survival compared with placebo in patients with metastatic gastric carcinoma who failed two lines of chemotherapy.

Conditions

Advanced or Metastatic Gastric Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

apatinib

Group Type: EXPERIMENTAL

apatinib

Intervention Type: DRUG

apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

placebo

Group Type: PLACEBO_COMPARATOR

placebo

Intervention Type: DRUG

placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Interventions

apatinib

apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Intervention Type: DRUG

placebo

placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• ≥ 18 and ≤ 70 years of age
• Histological confirmed advanced or metastatic adenocarcinoma of the stomach
• Have failed for at least 2 lines of chemotherapy
• Life expectancy of at least 12 weeks.
• Eastern Cooperative Oncology Group Performance Status of 0 or 1 within 1 week before randomization.
• At least one measurable lesion beyond stomach (larger than 10 mm in diameter by spiral CT scan)
• Duration from the last therapy is more than 6 weeks for nitroso or mitomycin
• More than 4 weeks for operation or radiotherapy
• More than 4 weeks for cytotoxic agents or growth inhibitors
• Adequate hepatic, renal, heart, and hematologic functions (HB ≥ 90g/L,platelets > 80 ×10 E+9/L, neutrophil > 1.5 × 10 E+9/L, serum creatinine ≤ 1× upper limit of normal(ULN), bilirubin < 1.25× ULN, and serum transaminase ≤ 2.5× ULN).

Exclusion Criteria

• Pregnant or lactating women
• History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix Hypertension and unable to be controlled within normal level following treatment of anti-hypertension agents (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg).
• Any factors that influence the usage of oral administration; Evidence of Central Nerves System(CNS) metastasis
• Intercurrence with one of the following: coronary artery disease, arrhythmia ,heart failure and proteinuria ≥ (+)
• International Normalize Ratio (INR) > 1.5 and activated partial thromboplastin time（APPT） > 1.5 × ULN
• Abuse of alcohol or drugs
• Certain possibility of gastric or intestine hemorrhage
• Less than 4 weeks from the last clinical trial
• Prior VEGFR inhibitor treatment
• Disability of serious uncontrolled intercurrence infection Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, Pneumoconiosis, radiation pneumonitis, drug-related pneumonia, Pulmonary function damaged seriously etc.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Fudan University

OTHER

Sponsor Role: collaborator

The 81 Hospital of PLA

UNKNOWN

Sponsor Role: collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jin Li, MD, PHD

Role: PRINCIPAL_INVESTIGATOR

Fudan University

Shukui Qin, MD

Role: PRINCIPAL_INVESTIGATOR

The 81 Hospital of PLA

Locations

The 81 Hosiptal of PLA

Nanjing, Jiangsu, China

Fudan University cancer hospital

Shanghai, Shanghai Municipality, China

Countries

China

Other Identifiers

HENGRUI 20101208

Identifier Type: -

Identifier Source: org_study_id